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A B S T R A C T
Vitamin D, whose levels vary seasonally with sunlight, is activated to 1a,25-dihydroxyvitamin D3 that
binds the vitamin D receptor (VDR) and transcriptionally regulates intestinal CYP3A4 expression. We
genotyped VDR polymorphisms and determined their associations with intestinal CYP3A4 and with
midazolam pharmacokinetics, and whether intestinal CYP3A4 levels/activity varied seasonally. The VDR
BsmIG>A (rs1544410) polymorphism was signiﬁcantly associated with CYP3A4 jejunal expression/
activity, with CYP3A4 duodenal mRNA, and with midazolam area under the curve (AUC). Intestinal
CYP3A4 expression/activity was signiﬁcantly higher in biopsies with the VDR promoter polymorphisms
Cdx2-3731G>A and GATA-1012A>G that increase VDR activation of target genes. Duodenal CYP3A4
mRNA was signiﬁcantly higher between April and September than between October and March.
Midazolam p.o. AUC and oral bioavailability trended higher October through March compared to April
through September. These data suggest VDR polymorphisms are predictors of intestinal CYP3A4, and that
CYP3A4 intestinal expression varies seasonally – likely related to annual changes in UV sunlight and
vitamin D levels.
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CYP3A4 is highly expressed in human duodenal and jejunal
mucosal epithelium [1,2]. Inter-individual differences in intesti-
nal CYP3A4 expression and activity contribute signiﬁcantly to the
low and variable oral bioavailability for many CYP3A4 drug
substrates. For example, it was estimated that intestinal CYP3A4
catalyzes the ﬁrst pass loss of >40% (on average) of an oral dose of
midazolam [3,4]. Moreover, for midazolam, the extent of
intestinal ﬁrst-pass extraction can vary between negligible to
as much as 75% [4]. This result is consistent with the more than 20-
fold inter-individual differences in CYP3A4 content in human
duodenal enterocytes [5–7]. These ﬁndings have important
therapeutic implications because the large inter-patient differ-
ences in ﬁrst-pass intestinal extraction efﬁciency leads to
differences in systemic exposure to the parent drug and its
metabolites. These differences are important determinants of
drug efﬁcacy and toxicity, and hence therapeutic outcome after
oral drug administration.
Inter-individual differences in intestinal CYP3A4 expression are
likely governed by both genetic and environmental factors.
However, numerous studies have revealed that CYP3A4 cis-
nucleotide variation cannot fully explain variable CYP3A4 expres-
sion in liver, or the oral or intravenous clearance of the CYP3A4
substrate midazolam [8]. Genetic variation in liver-enriched
transcription factors (e.g., PXR and FoxA2) regulating CYP3A4
expression appears to explain some of the variability in hepatic
CYP3A4 expression [9,10]. This suggests that genetic variation in
transcription factors governing intestinal CYP3A4 expression
might contribute to inter-individual differences in gut CYP3A4
expression.
There are multiple lines of evidence supporting the hypoth-
esis that CYP3A4 intestinal expression is highly regulated by the
biologically active form of vitamin D3 (1a,25-dihydroxyvitamin
D3 (VD3)). Treatment of intestinal cells with VD3 increases
CYP3A4 expression [11]. CYP3A4 transcription is induced by
VD3 activating the vitamin D receptor (VDR) which binds to
proximal elements in the CYP3A4 promoter [12] and distal ER6
and CLEM4 ER6 response element [13,14] to induce CYP3A4
transcription. In vivo, treatment of rats and mice with VD3
increases intestinal CYP3A protein expression and activity [7].
Likewise, humans treated with vitamin D supplementation show
a decreased AUC and increased clearance of the CYP3A substrate
atorvastatin [15]. Finally, it was recently shown that blood levels
of tacrolimus and sirolimus showed striking seasonal variation
that correlated with documented levels of ultraviolet light and
serum vitamin D3 levels [16] further supporting the role of the
vitamin D receptor as an important regulator of human
intestinal CYP3A expression.
In the present study we tested the hypothesis that common VDR
polymorphisms, each previously associated with VDR expression/
function in vitro and in vivo, would be associated with intestinal
CYP3A4 expression and activity, and further that intestinal CYP3A4
expression and midazolam disposition in vivo would show
seasonal variation correlating with the documented seasonal
availability of ultraviolet light and vitamin D levels.
2. Materials and methods
2.1. Study populations
Institutional Review Boards at the University of Washington
approved the use of tissue samples from organ donors, and at the
University of Indiana approved the midazolam study protocols,
and at St. Jude Children’s Research Hospital approved genotyping
of DNA from anonymous subjects. The Health Sciences ResearchEthics Board at the University of Western Ontario approved the
study protocol.
2.2. Human jejunal mucosa cohort
Human jejunal mucosa cohort (n = 30) from White donors was
obtained from the University of Washington School of Pharmacy
Human Tissue Bank (Seattle, WA). Both intestinal and hepatic
tissues (below) were obtained through the solid organ donation
program operated by Life Center Northwest, following informed
consent by the family for use of the tissues for research.
Demographic information for the jejunal and liver donors (below)
and detailed methods of CYP3A4 protein immunoquantitation and
activity, as measured by midazolam hydroxylation, have been
described earlier [17]. Unfortunately, it was not possible to
measure VDR protein in these samples. The considerable measures
taken to ensure cellular viability and preserve CYP protein and
activity from tissue harvest to freezing have been extensively
detailed previously [1,17]. Anecdotally, we have found no evidence
of CYP3A4 protein and mRNA degradation in the frozen, banked
tissue samples when measured periodically over the last 15 years.
2.3. Human liver cohort
Human liver cohort (n = 54) from White donors was obtained
from the University of Washington School of Pharmacy Human
Tissue Bank (Seattle, WA). All subjects’ families provided written
informed consent prior to tissue procurement. The considerable
measures taken to ensure cellular viability and preserve CYP
protein and activity from tissue harvest to freezing have been
extensively detailed previously [17]. The amount of CYP3A4
protein, midazolam hydroxylase activity, and CYP3A5 genotypes
have been previously described [17].
2.4. Human duodenal biopsy cohort
Human duodenal biopsy cohort from White donors consisted of
45 subjects. The mean age was 53.1  14.7 years (range 18–78). A
single 4-mL blood sample was collected on the day of the procedure
for DNA extraction using a DNA blood midi extraction kit (Qiagen,
Valencia, CA). Duodenal biopsies were obtained from healthy subjects
undergoing diagnostic esophagogastro-duodenoscopy at the London
Health Sciences Centre – Victoria Campus as part of their medical
care, and who were invited to participate in the study. No subject gave
more than a single biopsy. All subjects provided written informed
consent prior to sample procurement. During the subject’s scheduled
endoscopic procedure, an additional pinch biopsy was collected from
the duodenum at or slightly distal to the ampulla of Vater. The
Pathologists reviewing the slides of these biopsies indicated they are
all histologically normal.
2.5. Duodenal CYP3A4 expression
The duodenal specimen was immediately placed in RNAlater
according to the manufacturer’s instructions (Qiagen, Valencia,
CA) and stored at 80 8C until analysis. Tissue was homogenized
and RNA extracted in Trizol (Invitrogen, Carlsbad, CA) following
standard methods. The cDNA synthesis was performed with
500 ng of RNA. Quantitative RT-PCR for CYP3A4 was performed
using a SYBR green assay (Applied Biosystems, Foster City, CA)
with the following primers: 50-CAGGAGGAAATTGATGCAGTTTT-
30 (forward), and 50-GTCAAGATACTCCATCTGTAGCACAGT-30 (re-
verse). All samples were compared to a standard curve of the
CYP3A4 amplicon, which was sub-cloned into pCR2.1 TOPO1
(Invitrogen, Carlsbad, CA) for quantitative determination of copy
number.
Table 1
Methods used to genotype VDR polymorphisms.
SNP ID Genotyping method Assay detail
rs2228570 RFLP FW 50-AGCTGGCCCTGGCACTGACTCTGCTCT-30
FokI T>C RV 50-ATGGAAACACCTTGCTTCTTCTCCCTC-30
g.30920T>C Annealing: 58 8C
E2-T4C Digest: FokI, 37 8C for 2 h
rs1544410 RFLP FW 50-CAACCAAGACTACAAGTACCGCGTCAGTG-30
BsmI G>A RV 50-AACCAGCGGGAAGAGGTCAAGGG-30
g.63980G>A Annealing: 60 8C
E8-G + 284A Digest: BsmI, 65 8C for 2 h
rs7975232 RFLP FW 50-CAACCAAGACTACAAGTACCGCGTCAGTG-30
ApaI T>G RV 50-CACTTCGAGCACAAGGGGCGTTAGC-30
g.64978T>G Annealing: 65 8C
E9-T-48G Digest: ApaI, 37 8C for 2 h
rs731236 RFLP FW 50-CAACCAAGACTACAAGTACCGCGTCAGTG-30
TaqI T>C RV 50-CACTTCGAGCACAAGGGGCGTTAGC-30
g.65058T>C Annealing: 65 8C
E9-T32C Digest: TaqI, 65 8C for 2 h
rs4516035 TaqMan assay Assay ID C___2880805_10
GATA-1012A>G
rs11568820 TaqMan assay Assay ID C___2880808_10
Cdx2-3731G>A
Genomic positions refer to VDR reference sequence NG_008731.
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A total of 86 MDZ levels were available from 62 Whites
(complete demographics described previously [8]). Forty-three
Whites had a single measure, and nineteen Whites had repeated
measures. Study design for in vivo midazolam phenotyping from
multiple clinical trials has previously been described in detail [8].
Brieﬂy, in each study single-dose MDZ was administrated both i.v.
(intravenously) and p.o. (by mouth). In ﬁve studies, subjects were
simultaneously administered a single i.v. dose (0.05 mg/kg over
30 min) of MDZ and an oral dose of 15N-MDZ (3 mg) after an
overnight fast. In the additional two studies, oral MDZ (4 mg) was
administered 24 h after the i.v. dose. All drugs and food known to
affect CYP3A activity were prohibited before and for the duration of
the studies. For each subject, blood samples for MDZ concentra-
tions were obtained over a period of 12–24 h. Weight-corrected
p.o. clearance, dose adjusted p.o. area under the concentration–
time curve (AUC), and bioavailability (F) were used as MDZ PK
parameters, since dosages were different in these clinical trials and
body size appears to be an important determinant of between-
subject variability.
2.7. Genotyping for VDR polymorphisms
We genotyped VDR polymorphisms rs1544410 (intron 8 BsmI-
G>A), rs7975232 (intron 8 ApaI-T>G), rs731236 (exon 9 TaqI-
T>C), rs2228570 (exon 2 FokIT>C), rs11568820 (Cdx2-3731G>A)
and rs4516035 (GATA-1012A>G). Genomic DNA was extracted
from blood using the DNA blood midi kit (Qiagen, Valencia, CA) and
quantiﬁed by Pico Green assay (Invitrogen, Carlsbad, CA) and was
utilized to determine genotypes. Many of the genotypes were
determined by direct DNA sequencing (Hartwell Center) and
Taqman Allelic Discrimination Assays. Alternatively, genomic DNA
was ampliﬁed using primers (St Jude Hartwell Center, Memphis,
TN) and conditions listed in Table 1. The PCR products were
digested with the selective restriction enzymes.
2.8. Statistical analysis
Only White subjects were used in all studies. Samples from the
duodenum and jejunum were not gender stratiﬁed beforegenotype/CYP3A phenotype analysis because gender had no effect
on intestinal CYP3A4 protein expression or activity [6]. Midazolam
PK measures were not gender stratiﬁed because oral dose-adjusted
AUC and bioavailability were not different between men and
women [8]. In vivo MDZ PK data was not corrected for CYP3A5
expressor/non-expressor or CYP3A4*1B genotypes because it was
previously determined, in these exact same samples, that there
were no signiﬁcant differences in MDZ PK parameters between
genotypes [8]. To date, there is no good explanation for the lack of
genotype–phenotype concordance for the effect of CYP3A5
expression on MDZ metabolism in vitro but not in vivo [8]. In
the midazolam cohort, if a subject contributed more than one
sample, the sample average value was used to avoid over-
weighting of subjects with repeated sampling. The Chi-squared
test for deviation from Hardy–Weinberg equilibrium was used to
calculate the observed versus expected distribution of genotypes.
Because the phenotypic markers were not normally distributed,
group differences were analyzed nonparametrically using the
Wilcoxon rank sum test, which is more robust against outliers, to
compare binary groups (e.g., GG + GT versus TT). The Kruskal–
Wallis test was used to compare three groups of genotype for each
polymorphism (e.g., GG versus GT versus TT) with the phenotype.
To test for seasonal differences, the months were grouped into
the six months with the highest (April through September) and the
lowest (October through March) historical average daily UV-B
Index in Western Ontario and Indiana regions [18,19]. The
Wilcoxon rank sum test was used to test for seasonal differences
in duodenal CYP3A4 mRNA expression. To evaluate seasonal
effects for the midazolam cohort, if the subject had more than one
observation in the same season, the median value was used, an
accepted statistical approach [16]. If the subject had more than one
observation, but in different seasons, all individual values were
included. Thus, each subject would have one unique measurement
for each phenotype, unless he/she was measured in both seasons.
We then applied the Wilcoxon rank sum test to evaluate the
seasonal difference. All the statistical calculations were performed
using program R (version 2.8.1): A Language and Environment for
Statistical Analysis (http://www.Rproject.org). Unfortunately, nei-
ther the duodenum nor midazolam cohorts were large enough to
stratify by VDR genotype ﬁrst in order to test for signiﬁcant gene/
environment (season) interactions.
Fig. 1. The VDR BsmI polymorphism is associated with intestinal CYP3A4
phenotypes in White subjects. Jejunal CYP3A4 protein expression (expressed as
pmoles CYP3A4 protein normalized for total protein content in a homogenate of
jejunal mucosa) and midazolam10-OH hydroxylation activity, duodenal CYP3A4
mRNA expression, and MDZ AUC association with VDR BsmI G>A rs1544410
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3.1. The VDR BsmI polymorphism is signiﬁcantly associated with
intestinal CYP3A4 expression and activity in multiple White cohorts
We genotyped VDR polymorphisms rs1544410 (intron 8 BsmI-
G>A), and rs7975232 (intron 8 ApaI-T>G), and rs731236 (exon 9
TaqI-T>C) because these SNPs, and their associated RFLPs, have
been extensively tested for their association with multiple VDR
regulated traits [20]. The VDR BsmI genotype was signiﬁcantly
associated with jejunal CYP3A4 protein levels (AA: 3.8  9.1 < AG:
12.3  11.5 < GG: 21.2  8.0 pmol/mg homogenate; Kruskal–Wallis
p = 0.04) (Fig. 1); and with CYP3A4 midazolam hydroxylation (AA:
67.4  65.1 < GA: 154.8  117.5 < GG: 230.6  126.8 pmol/mg ho-
mogenate; Kruskal–Wallis p = 0.04) (Fig. 1). CYP3A5 is polymorphi-
cally expressed in human intestine [17]. VDR is known to induce
intestinal CYP3A4 [12], but is not expected to regulate CYP3A5 since
CYP3A5 lacks many of the VDR response elements, and is not an
inducible member of the CYP3A family [12]. Hence, we did not test for
association of VDR genotype with CYP3A5 expression. However, since
CYP3A5 expression clearly affects midazolam hydroxylation in vitro
[12], we determined the effect of VDR polymorphisms on MDZ
hydroxylation in jejunum homogenates with and without CYP3A5 in
our analysis. The association between CYP3A4 activity and VDR
genotype remained signiﬁcant even after removing CYP3A5 expres-
sers (p = 0.04).
A similar result was seen in duodenal biopsies from White
donors (Fig. 1) with CYP3A4 mRNA expression levels correspond-
ing with BsmI genotype (GG > GA > AA). Subjects with at least one
BsmI-A allele had signiﬁcantly lower intestinal CYP3A4 mRNA
levels as compared to BsmI-G homozygous subjects (Fig. 1). The
TaqI and ApaI polymorphisms, in partial LD with the BsmI
polymorphism [21], showed a less signiﬁcant association with
intestinal CYP3A4 expression and activity (p = 0.05).
Next we took advantage of unique samples in which
midazolam, a drug selectively metabolized by CYP3A to its
primary metabolite, 10-hydroxymidazolam, was administered
orally and intravenously. The apparent clearance of orally
administered MDZ is recognized as a biomarker of intestinal
CYP3A and hepatic CYP3A activities, while the intravenous MDZ
reﬂects predominantly hepatic CYP3A. The simultaneous p.o./i.v.
administration of MDZ was previously used to examine the
individual contribution of intestinal CYP3A to metabolism [8].
Consistent with BsmI GG subjects having higher intestinal levels
of CYP3A (Fig. 1) and a more rapid weight adjusted oral clearance of
midazolam (p = 0.05), the dose adjusted midazolam oral AUC was
lower in subjects with the VDR BsmI-G genotype. This inverse
relationship is exactly what would be expected since higher
intestinal CYP3A4 would be associated with higher CL/F, but lower
bioavailability and AUC.
3.2. VDR genotypes are not associated with hepatic CYP3A4
We hypothesized that the VDR genotypes would be associated
with intestinal and not hepatic CYP3A4 expression because VDR is
not highly expressed in human hepatocytes [22]. We VDR
genotyped human livers from 54 White donors that had previously
been phenotyped for CYP3A4 protein expression and activity, and
that were all CYP3A5 non-expressors [17]. There was nogenotypes (listed at the bottom of each cohort panel). Box plots indicate 1st and
third quartiles, bold interior line within boxes represent median values, bars
represent ranges after outliers were excluded, and circles outside of boxes represent
outliers. The p-value results from the Kruskal–Wallis nonparametric test is shown
for comparing the signiﬁcance between the three genotypes. n = number of
subjects.
Fig. 2. VDR promoter polymorphisms are associated with intestinal CYP3A4 phenotypes in White subjects. Left panel: jejunal CYP3A4 protein, MDZ AUC and duodenal CYP3A4
mRNA expression associated with the VDR 1012 promoter (GATA binding site) genotypes (listed at the bottom of the each panel). Right top panel: jejunal CYP3A4 protein
and MDZ AUC association with VDR 3731 promoter (CDX2 binding site) genotypes. Right bottom panel: jejunal CYP3A4 protein and 10-OH MDZ activity associated with the
combined VDR 3731/1012 genotypes. Box plots are described in Fig. 1, the p-value results from the Kruskal–Wallis nonparametric test is shown when comparing the
signiﬁcance of three genotypes, and the p-value results from the Wilcoxon test is shown when comparing the signiﬁcance of two genotypes. n = number of subjects.
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expression or midazolam 10-hydroxylase activity (p = 0.51). In
addition, we tested for but found no signiﬁcant association
between the intravenous midazolam clearance and VDR BsmIgenotype (p > 0.05). This result is consistent with the limited
expression of VDR in the liver [23] and the lack of an association
between hepatic CYP3A4 content measures and VDR BsmI
genotype.
Fig. 3. Seasonal variation in CYP3A4 duodenum expression in White donors. Box plots (described in Fig. 1) indicate the CYP3A4 mRNA expression in human duodenums
grouped monthly (July and November had no individuals) (left panels) and grouped seasonally from April–September versus October–March (right panels). The p-value
results from the Wilcoxon test are shown for the right panel comparing CYP3A4 mRNA expression in April–September versus October–March.
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CYP3A4 traits
The common rs2228570 (exon 2 FokIT>C) was genotyped
because it results in a three amino acid shorter VDR protein with
reported higher transcriptional activity [20]. The FokI RFLP has no
LD with any of the other VDR SNPs or LD blocks [21], and was not
associated with intestinal CYP3A4 (p > 0.05).
3.4. VDR promoter polymorphisms are associated with intestinal
CYP3A4 expression and activity in White subjects
We genotyped for VDR promoter polymorphisms rs11568820
(Cdx2-3731G>A) and rs4516035 (GATA-1012A>G) because these
affect binding sites for Cdx2 and GATA, respectively, and VDR
transcriptional activity [24,25]. CYP3A4 jejunal protein (Fig. 2) and
activity (p = 0.03) were higher in subjects with the GATA-A
genotype (that creates a VDR promoter GATA binding site) [24]
and were higher in subjects with the Cdx2-A alleles (that increases
Cdx2 binding to the VDR promoter) [25] (Fig. 2), and with the
combined GATA/Cdx2 A/A genotype. Consistent with this ﬁnding,
the midazolam AUC was lower in those subjects who had the
GATA-A and Cdx2-A promoter genotypes (Fig. 2). Surprisingly, the
CYP3A4 mRNA showed the opposite trend with higher mRNA in
subjects with the GATA-G genotype (Fig. 2).
3.5. Duodenal CYP3A4 mRNA expression and midazolam in vivo PK
parameters show seasonal variation in expression
Because circulating levels of vitamin D are known to be directly
related to seasonal levels of UV sunlight, we compared CYP3A4
expression monthly and by seasons in the subjects sampled in
London, Ontario, Canada (latitude 42.978N). Duodenal CYP3A4
mRNA levels showed month-to-month variation (Fig. 3). Based on
data published for historical UV-B levels across the upper mid-
West and in Toronto [18,19], the mean CYP3A4 levels were
compared between the six months when surface UV-B irradiance
was historically between 55% and 100% of maximum (April
through September), and the six months when the UV-B surface
irradiance levels were below these values (October through
March). The mean CYP3A4 levels in the duodenum were highest
in the six months with the highest documented levels of UV-B
(Fig. 3) and the difference was signiﬁcant (p = 0.01).
There was a trend toward a decrease in midazolam dose
adjusted AUC and oral bioavailability (Fig. 4) in the six months withthe highest UV-B levels in the upper Midwest [18] (April through
September) compared to the six months with the lowest UV-B
levels (October through March) in the subjects analyzed in
Indianapolis, IN (latitude 39.778N), although the difference did
not reach statistical signiﬁcance. Unfortunately, neither the
duodenum nor midazolam cohorts were large enough to stratify
by VDR genotype ﬁrst in order to test for signiﬁcant gene/
environment (season) interactions.
4. Discussion
Although it has been suggested that nearly all of the observed
differences in CYP3A catalyzed activity (90%) can be attributed to
genetic variation [26], there are relatively few examples where
CYP3A cis-genetic variation has been deﬁnitively linked to
differences in CYP3A dependent drug clearances in vivo
[9,10,27]. In this study we tested the hypothesis that VDR genetic
variation was related to CYP3A4 intestinal expression and activity.
Our investigation revealed that the same VDR genotypes predictive
of CYP3A4 expression in human duodenum and jejunum were also
associated with oral disposition of the CYP3A4 substrate mid-
azolam. These results add to our growing understanding of the
genetic determinants of intestinal CYP3A4 expression and
individual differences in ﬁrst pass intestinal extraction efﬁciency
following oral administration of CYP3A4 substrates.
The VDR BsmI polymorphism, in particular, showed association
with CYP3A4 intestinal expression/activity (BsmI-G allele = higher
CYP3A4 expression). The VDR BsmI RFLP, in combination with the
ApaI, TaqI RFLPs, that are in partial LD in Whites [21], have been
used extensively in association studies with multiple VDR
regulated traits, including bone mineral density and risk of
osteoporosis [20,28]. The relationship of the BsmI RFLP to bone
density is controversial with some groups ﬁnding increased bone
density while others have found reduced bone density [28].
The Cdx2-3731A and GATA-1012A (upstream of exon 1a)
promoter genotypes, particularly in combination, were associated
with higher CYP3A4 intestinal expression/activity. Although VDR
uses multiple promoters, the 1a promoter is transcriptionally the
most active [29]. Both Cdx2 and GATA are intestinal transcription
factors important for regional differences in expression of genes
along the small intestine [30]. Cdx2 is expressed at higher levels in
the distal compared with the proximal small intestine. In contrast,
GATA4 is expressed as a gradient from highest in duodenum to
absent in ileum [31]. The regional differences in the ratios of Cdx2/
GATA4 in duodenum and jejunum may help explain the surprising
Fig. 4. Seasonal variation in oral midazolam pharmacokinetic parameters in White subjects. Box plots (described in Fig. 1) indicate the midazolam PK parameters grouped
monthly (left panels) and grouped seasonally from April–September versus October–March (right panels). AUC is the midazolam dose adjusted area under the concentration-
time curve, F is the midazolam bioavailability, and CL is the weight-corrected p.o. clearance of midazolam. The p-value results from the Wilcoxon test are shown for the right
panels comparing the signiﬁcance of CYP3A4 traits in April–September versus October–March. N.S. = no signiﬁcant difference observed under the 5% signiﬁcance level.
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higher jejunal, but lower duodenal, CYP3A4 expression (Fig. 2).
These promoter genotypes appear directly associated with VDR
expression levels because, compared with the -3731 Cdx2-A allele,
the -3731Cdx2-G allele leads to a decrease in Cdx transactivation
of the VDR exon 1a promoter and is associated with a 10% decrease
in spinal bone mineral density in Japanese women [24]. Similarly,
we found that CYP3A4 jejunal levels were lower in intestines with
the Cdx2-G allele. The VDR -1012A GATA+ (but not -1012G
GATA) genotype binds GATA in electromobility shift assays [21].
Correspondingly, in transfected cells, VDR promoter-reporter
constructs containing the GATA binding site had a 50% lower
transcription rate compared with the GATA+ reporter plasmid [21].
These results suggest that the higher CYP3A4 expression in
intestines with the VDR/GATA+ allele would correspond to greaterGATA4 transactivation of the VDR promoter and correspondingly
higher VDR levels in these intestines, although this was not
formally tested. Importantly, the GATA and -3731Cdx-2-G
promoter polymorphisms are combined in a risk haplotype for
fracture [21], and we found that CYP3A4 expression/activity was
signiﬁcantly lower in jejunums with the combined GATA/-3731G
genotype (Fig. 2). The differences observed for midazolam
clearance (50% higher CL/F for the VDR BsmI variant and 50%
lower CL/F for the GATA variant) may not have clinical signiﬁcance
for midazolam because the drug is generally dosed to a desired
pharmacological effect (sedation). However, these differences
would be clinically meaningful for a narrow therapeutic index
CYP3A substrate like tacrolimus, particularly if the extent of
intestinal ﬁrst-pass extraction is much higher than that of
midazolam.
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in regulating intestinal CYP3A4, the role for VDR in regulating
hepatic CYP3A4 is more controversial and weak. Early reports
found that VDR was only expressed in non-parenchymal cells and
biliary epithelial cells and not in hepatocytes [22]. Some
investigators have reported that VDR is expressed in isolated
human hepatocytes [32,33]. However, the expression level of VDR
in rat liver is very low, about 0.1% compared to that in rat intestine
[23]. Even greater differences in VDR mRNA content are found in
intact human liver versus intestine [7,34]. Moreover, the magni-
tude of CYP3A4 mRNA induction reported in human liver slices by
VD3 was only 2-fold (compared to 10-fold by dexamethasone, a
relatively weak inducer of human CYP3A4) [23]. Finally, the VDR
BsmI polymorphism had no association with hepatic CYP3A4
expression (p = 0.51).
Lindh et al. [16] recently demonstrated that dose adjusted blood
levels of sirolimus and tacrolimus (CYP3A substrates) in patients in
Stockholm, Sweden (59.178N) were higher in winter months and
lower in summer months, directly correlating with seasonal
differences in UV sunlight levels and systemic vitamin D3 levels in
Finland (648N) and Sweden, respectively. However, it remained to
be determined whether intestinal (or hepatic) CYP3A4 levels were
similarly related to seasonal variation in UV sunlight. In addition,
because the seasonal variation in the availability of UV light is
much greater at the northern latitudes, and diminishes as one
moves closer to the equator, it was unclear whether the results
would be the same among persons living in lower latitudes. The
results from this exploratory retrospective study clearly demon-
strate that documented seasonal changes in UV sunlight around
London, Ontario, Canada (latitude 42.978N) [18,19] correlated with
human duodenal CYP3A4 levels. CYP3A4 intestinal expression was
signiﬁcantly higher in the six months with the highest historical
UV-B levels compared to the six months with the lowest UV-B
levels. The trend toward decreased midazolam oral bioavailability
in the months with high UV-B levels around Indianapolis, IN
(latitude 39.778N) [18], and with higher intestinal CYP3A4,
demonstrates that it is variation in intestinal CYP3A4, and not
seasonal variation in CYP3A4 systemic/hepatic clearance, that is
driving the apparent seasonal differences in midazolam oral
bioavailability.
We acknowledge that a large prospective clinical study to
simultaneously measure serum 25(OH)D blood levels and CYP3A4
pharmacokinetics is the gold standard. However, the availability of
these unique retrospective samples from three separate human
clinical studies of extensively CYP3A phenotyped samples allowed
us to move immediately and rapidly forward in testing our
hypothesis. We think this is a distinct advantage since, realistically,
a prospective clinical trial would require 2+ years to run and cost
hundreds of thousands of dollars. The signiﬁcant association of
intestinal CYP3A4 expression with seasonal variation in UV
sunlight in the upper Midwest [18,19] is notable since none of
these studies was designed to test for this relationship and hence
did not control for all of the potential confounders (e.g., vitamin D
supplements or travel to areas with higher UV sunlight) that would
affect average UV exposure/vitamin D levels.
In summary, our results demonstrate that genetic variation in
VDR, a direct transcriptional activator of intestinal CYP3A4, is
associated with CYP3A4 duodenal and jejunal expression. More-
over, CYP3A4 intestinal expression varied seasonally, correlating
with the documented levels of UV sunlight and reported seasonal
levels of vitamin D. Hence, variation in VDR and its ligand appear to
be primary determinants of individual variation in intestinal
CYP3A4 expression. These results suggest that VDR genotypes may
help explain individual differences in ﬁrst pass intestinal extrac-
tion efﬁciency following oral administration of drugs that are
substrates of CYP3A4, and perhaps of other intestinal VDRregulated drug detoxiﬁcation genes including P-glycoprotein
and CYP2C9 [35,36]. Our results support further testing for how
seasonal, regional, racial and ethnic differences in vitamin D levels
correlate with CYP3A4 mediated drug clearance. Comprehensive
testing for VDR genotype/UV sunlight-vitamin D levels will require
inclusion of larger populations but also more comprehensive,
standardized, and precise approaches to capturing environmental
information.
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